Adjuvant interferon alfa-2a treatment in reseeted primary stage II cutaneous melanoma

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1425-1429

  Pehamberger, Hubert ^a   Soyer, H Peter ^a   Steiner, Andreas ^a   Kofler, Regina ^a   Binder, Michael ^a   Mischer, Paul ^a   Pachinger, Wolf ^a   Auböck, Josef ^a   Fritsch, Peter ^a   Kerl, Helmut ^a   Wolff, Klaus ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPERTHYROIDISM; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 7144264391     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1425     Document Type: Article

References (32)

1. American Cancer Society: Cancer Facts and Figures, 1995. Publication no. 5008.95. Atlanta, GA, American Cancer Society, 1995
2. MacKie RM: Melanocytic nevi and malignant melanoma, in Champion RH, Burrow JJ, Ebling FSS (eds): Rook/Wilkinson/Ebling Textbook of Dermatology (ed 5). London, United Kingdom, Blackwell Scientific, 1992, pp 1525-1560
3. Morbidity and Mortality Weekly Reports, Centers for Disease Control. Deaths From Melanoma - United States 1973-1992. Arch Dermatol 131:770-772, 1995
4. Johnson TM, Smith JM II, Nelson BR, et al: Current therapy for cutaneous melanoma. J Am Acad Dermatol 32:689-697, 1995
5. Balch CM, Houghton AN, Milton GW, et al: Cutaneous Melanoma (ed 2). Philadelphia, PA, Lippincott, 1992
6. Pehamberger H, Binder M, Steiner A, et al: In vivo epiluminescence microscopy: Improvement of early diagnosis of melanoma. J Invest Dermatol 100:356s-362s, 1993
7. Soyer HP, Smolle J, Kerl H, et al: Early diagnosis of malignant melanoma by surface microscopy (letter). Lancet 2:856, 1987
8. Pehamberger H, Binder M, Knollmayer S, et al: Immediate effects of a public education campaign on prognostic features of melanoma. J Am Acad Dermatol 29:106-109, 1993
9. Doherty VR, MacKie RM: Experience of a public education program on early detection of cutaneous malignant melanoma. Br Med J 297:388-391, 1988
10. Frank SJ, Meyers M: Interferon as adjuvant therapy for high risk melanoma. Melanoma Lett 13:1-4, 1995
11. Parkinson DR, Houghton AN, Hersey P, et al: Biologic therapy for melanoma, in Balch CM, Houghton AN, Milton GW, et al (eds): Cutaneous Melanoma (ed 2). Philadelphia, PA, Lippincott, 1992, pp 523-524
12. Kirkwood J, Ernstoff M: Role of interferons in the therapy of melanoma. J Invest Dermatol 95:180s-184s, 1990
13. Kirkwood JM, Ernstoff MS: Interferons - Clinical applications: Cutaneous melanoma, in DeVita VTJ, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, 1991, pp 311-333
14. Legha SS: Current therapy tor malignant melanoma. Semin Oncol 16:34-44, 1989
15. Steiner A, Wolf Ch, Pehamberger H: Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN α, r-IFN γ and r-IFN α + cimetidine) in disseminated malignant melanoma. J Cancer Res Clin Oncol 113:459-465, 1987
16. Cascinelli N, Bufalino R, Morabito A, et al: Results of adjuvant interferon study in WHO melanoma programme. Lancet 343:913-914, 1994
17. Cascinelli N: Evaluation of efficacy of adjuvant rIFNα 2A in melanoma patients with regional node metastases. Proc Am Soc Clin Oncol 14:410, 1995 (abstr)
18. Creagan ET, Dalton RJ, Ahmann DL, et al: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13:2776-2783, 1995
19. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14:7-17, 1996
20. Malignant melanoma of the skin (excluding eyelid), in Beahrs OH, Henson DE, Hutter RVP, et al (eds): American Joint Committee on Cancer Manual for Staging of Cancer (ed 4). Philadelphia, PA, Lippincott, 1992, pp 143-148
21. Drake LA, Ceilley RI, Cornelison RL: Guidelines of care for malignant melanoma. J Am Acad Dermatol 28:638-641, 1993
22. Clark WH Jr, From L, Bernadino EA, et al: The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res 29:705-727, 1969
23. Breslow A: Thickness, cross sectional areas, depth of invasion in the prognosis of primary melanoma. Ann Surg 172:902-908, 1970
24. Maize JC, Ackerman AB: Pigmented Lesions of the Skin. Philadelphia, PA, Lea & Febiger, 1987, pp 225-270
25. Ackerman AB, Cerroni L, Kerl H: Pitfalls in Histopathologic Diagnosis of Malignant Melanoma. Philadelphia, PA, Lea & Febiger, 1994
26. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48. Geneva, Switzerland, WHO, 1979
27. Grob JJ, Dreno B, Delaunay M, et al: Results of the French multicenter trial on adjuvant therapy with interferon alfa-2a in resected primary melanoma (> 1.5 mm). Proc Am Soc Clin Oncol 15:437, 1996 (abstr)
28. Bajetta E, Di Leo A, Zampino MG, et al: Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 12:806-811, 1994
29. Veronesi U, Adamus J, Bandiera DC, et al: Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 297:627-630, 1977
30. Sim FH, Taylor WF, Ivins JC, et al: A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Cancer 41:948-956, 1978
31. Lyons JH, Cockerell CJ: Elective lymph node dissection for melanoma. J Am Acad Dermatol 30:467-480, 1994
32. Balch CM, Sooung SJ, Bartolucci AA, et al: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years and younger. Ann Surg 224:255-266, 1996